Loading component...
Loading component...
N0 Report Explained - Patients Age >50 / RS 0-25
N0 Report Explained - Patients Age >50 / RS 26-100
N0 Report Explained - Patients Age <50 / RS 0-15
N0 Report Explained - Patients Age <50 / RS 16-25
N0 Report Explained - Patients Age <50 / RS 26-100
Loading component...
MDT Live 2025
Helping guide treatment decisions in HR+, HER2-, early breast cancer patients
Loading component...
MDT Live October 2024
Helping guide treatment decisions in HR+, HER2-, early breast cancer patients
Loading component...
MDT Live March 2024
Our 2nd in the series where breast cancer clinicians come together to discuss HR+, HER2- early invasive breast cancer cases.
Loading component...
MDT Live 2023
Helping guide treatment decisions in HR+, HER2-, early breast cancer patients
Loading component...
Loading component...
May 2025
Loading component...
Shaping the future of treatment decision making using Multigene Assays (MGA): An expert round table
Focus on the Pre-Operative Genomic Testing was one of the Key Messages from the Exact Sciences Symposium at St. Gallen 2025. The session also included expert contributions from key opinion leaders where topics like systemic treatment decision-making, neoadjuvant strategies, and patient engagement were shared.
Directing Neoadjuvant Chemotherapy (NAC) using the Oncotype DX Breast Recurrence Score Result
Professor, Stephen Chia MD, FRCP(C)
Optimizing systemic treatment choices using the Oncotype DX Breast Recurrence Score Result pre-operatively
Professor Shani Paluch-Shimon
Genomic testing on excision sample vs core biopsy: What we can learn from PreDX?
Henry Cain
Patient perspectives: A round table discussion
Henry Cain
Loading component...
Welcome and Introduction
Professor Marc A. Thill
Unlocking the Oncotype DX Breast Recurrence Score® Test: Unique design and development to bring clarity to treatment decisions
Professor Frédérique Penault-Llorca
Advancing treatment approaches and neoadjuvant therapy in early breast cancer: Evidence-based strategies
Professor Marc A. Thill
Emerging Trends on Treatment Guidance in Early Breast Cancer: Unveiling clinical implications from latest updates from TAILORx and RxPONDER
Professor Christos Sotiriou
Loading component...
Evolving clinical practice for multi-gene assays: what’s new!
Gain insights from esteemed speakers Giuseppe Curigliano, Laura Biganzoli, and Christian Kurzeder as they discuss the implications and implementation of guidelines for MGAs in clinical practice, including expert discussion on challenging cases.
Implications of updated guidelines for MGAs: Introduction
Professor Giuseppe Curigliano provided with an overview of key takeaways from recently updated ESMO Guidelines and St. Gallen recommendation, focusing on MGA and their roles.
Implementation of guidelines into clinical practice: expert discussion on challenging cases - Large tumour
Professor Giuseppe Curigliano presented a challenging case study of early breast cancer with a large tumour, focusing on the use of ODX on Core Biopsy testing.
Implementation of guidelines into clinical practice: expert discussion on challenging cases - Elderly patient
Professor Laura Biganzoli presented a challenging case study of an elderly patient with early breast cancer, focusing on the important interplay between genomic tools and patients’ characteristics.
Challenging cases: N1 – premenopausal
Professor Christian Kurzeder presented a challenging case study of a N1 premenopausal patient, focusing on how ODX and clinical evidence may help guiding the treatment decision.
Loading component...
Insights from ESMO24 - Exact Sciences Educational Symposium
Tools to Guide Treatment Decisions in Early Breast Cancer: Genomic Testing and Emerging Role of MRD
![[ESMO24] Insights from ESMO24.](/_next/image?url=%2F-%2Fjssmedia%2Fproject%2Fheadless%2Foncotype%2Fen%2Fimages%2Fnews-and-resources%2Fvideos%2Fthumbnail_video_esmo24_insights.png%3Fh%3D610%26iar%3D0%26w%3D1084%26rev%3D-1%26hash%3D737CFDF8C7788963E5494F5C9659B20D&w=3840&q=75)
Evolving role of MRD guided decision making in early breast cancer
Prof. Sherene Loi presented at ESMO 2024 an update on the current data and ongoing studies on molecular residual disease in early breast cancer.
![[ESMO24] Evolving role of MRD guided decision making in early breast cancer.](/_next/image?url=%2F-%2Fjssmedia%2Fproject%2Fheadless%2Foncotype%2Fen%2Fimages%2Fnews-and-resources%2Fvideos%2Fthumbnail_video_esmo24_evolvingroleofmrd.png%3Fh%3D607%26iar%3D0%26w%3D1087%26rev%3D-1%26hash%3D18990D72646E0A1F99D09B5ED9D89D1C&w=3840&q=75)
Tissue-based genomics to guide adjuvant therapy decisions
Prof. Janice Walshe discusses the impact of the introduction of genomic assays on clinical practice for both clinicians and patients.
![[ESMO24] Tissue-based genomics to guide adjuvant therapy decisions.](/_next/image?url=%2F-%2Fjssmedia%2Fproject%2Fheadless%2Foncotype%2Fen%2Fimages%2Fnews-and-resources%2Fvideos%2Fthumbnail_video_esmo24_tissue.png%3Fh%3D610%26iar%3D0%26w%3D1093%26rev%3D-1%26hash%3D162ED16B16223AE79C2BBF357FC71917&w=3840&q=75)
Introduction to MRD in breast cancer
Prof. Nicholas Turner provides a brief overview of the concept and terms related to molecular residual disease
![[ESMO24] Introduction to MRD in breast cancer.](/_next/image?url=%2F-%2Fjssmedia%2Fproject%2Fheadless%2Foncotype%2Fen%2Fimages%2Fnews-and-resources%2Fvideos%2Fthumbnail_video_esmo24_introductiontomrd.png%3Fh%3D608%26iar%3D0%26w%3D1093%26rev%3D-1%26hash%3D019053DA612FDD25C837BED8A61F62E0&w=3840&q=75)
Evolving role of genomic assays in early breast cancer
Prof. Miguel Martin discusses the application of genomic assays in the neoadjuvant setting
![[ESMO24] Evolving role of genomic assays in early breast cancer.](/_next/image?url=%2F-%2Fjssmedia%2Fproject%2Fheadless%2Foncotype%2Fen%2Fimages%2Fnews-and-resources%2Fvideos%2Fthumbnail_video_esmo24_evolving.png%3Fh%3D611%26iar%3D0%26w%3D1081%26rev%3D-1%26hash%3DA129A41148175ADA1B21028FFDAE98F0&w=3840&q=75)
Loading component...
Patient's awareness and understanding of genomic testing
Richard Simcock, UK
Identifying patients for Oncotype DX® testing in my clinical practice
Christos Markopoulos, Greece
The Oncotype DX® Test: Evolution of UK Real World Outcomes Data
Miss Marianne Dillon, Consultant Oncoplastic Breast Surgeon from Swansea Bay University Health Board, Dr Wendy Taylor Consultant Clinical Oncologist...
Follow the evidence to help guide chemotherapy decisions for early breast cancer patients
Dr Richard Simcock, Consultant Clinical Oncologist, Brighton and Sussex University Hospitals NHS Trust, and Dr David Hyams, Medical Director
Clinical utility of multigene assays in early breast cancer: Predictive tests
A presentation by Professor Christos Markopoulos from the University of Athens in Greece talking about the predictive ability of multigene assay...
Landmark RxPONDER Trial results presented at the 2020 SABCS
New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score® results of 0-25.
Get in touch
Have questions about Oncotype DX®?
